Charakterisierung humaner IgM und IgA Varianten der anti-HIV-1 Antikörper 2F5 und 2G12
Abstract
We have previously generated human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1) antibodies 2F5IgG and 2G12IgG with an exceptional cross-clade neutralizing potential. 2F5IgG and 2G12IgG passively administrated to macaques were able to confer complete protection from both intravenous and mucosal challenge with pathogenic HIV-simian immunodeficiency virus chimeric strains and have shown beneficial effects in a phase-1 clinical trial. We now class-switch 2F5 and 2G12 to the immunoglobulin M (IgM) or IgA isotype, to enforce features like avidity, complement activation or the potential to neutralize mucosal transmission. For this purpose we express functional polymeric 2F5 and 2G12 antibodies in CHO cells and evaluate their anti-HIV-1 activity in vitro. Additionally, the impact of the class switch on the protective potential of 2F5 and 2G12 to inhibit HIV-1 infection of peripheral blood mononuclear cell cultures with several primary HIV isolates will be tested.
Schlagworte Neutralisierende Antikörper rekombinante Expression HIV
Publikationen
Mitarbeiter*innen
Renate Kunert
Univ.Prof. Dipl.-Ing. Dr.nat.techn. Renate Kunert
renate.kunert@boku.ac.at
Tel: +43 1 47654-79852
Projektleiter*in
01.01.1998 - 31.12.2000